SARS-CoV-2 sequencing with cloud-based analysis illustrates expedient co-ordinated

surveillance of viral genomic epidemiology across six continents

Authors

Daniel Amoako,[1] Nguyen To Anh,[2] Marc Brouard,[3] Constanza Campano Romero,[4] Andres

Castillo Ramirez,[4] Bede Constantinides,[3] Derrick Crook,[3,5] Phan Manh Cuong,[6] Moussa

Moise Diagne,[7] Amadou Diallo,[7] Nguyen Thanh Dung,[8] Laura Dunn,[5] Le Van Duyet,[6] Josie

Everatt,[1] Katherine Fletcher,[3] Philip Fowler,[3] Mailie Gail,[9] Saheer Gharbia,[10] Hospital for

Tropical Diseases SARS-CoV-2 testing team,[8] Nguyen Thi Thu Hong,[2] Martin Hunt,[3,12] Zam

Iqbal,[3,12] Katie Jeffery,[5] Dikeledi Kekana,[1] Thomas Kesteman,[2] Jeff Knaggs,[3,12] Marcela

Lopes Alves,[3] Dinh Nguyen Huy Man,[8] Amy J. Mathers,[11] Nghiem My Ngoc,[8] Sarah

Oakley,[5] Hardik Parikh,[11] Tim Peto,[3,5] Marcelo Rojas Herrera,[4] Nicholas Sanderson,[3] Vitali

Sintchenko,[9] Jeremy Swann,[3] Nguyen Thi Tam,[2] Le Van Tan,[2] Pham Ngoc Thach,[6] Ndeye

Marieme Top,[7] Nguyen Thu Trang,[2] Van Dinh Trang,[6] H. Rogier Van Doorn,[2] Anne von

Gottberg,[1,13] Nicole Wolter,[1,13] Bernadette C Young[3,5]

Affiliations

1. The National Institute for Communicable Diseases (NICD), a division of the National

Health Laboratory Service, Johannesburg,, Republic of South Africa

2. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

3. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

4. El Instituto de Salud Pública de Chile, Chile

5. Oxford University Hospitals NHS Trust, Oxford, United Kingdom

6. National Hospital for Tropical Diseases, Hanoi, Vietnam

7. The Institut Pasteur de Dakar, Senegal

8. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

9. Microbial Genomics Reference Laboratory, Institute of Clinical Pathology and

Medical Research, New South Wales Health Pathology, Sydney, Australia

10. National Infection Service, UK Health Security Agency, London, United Kingdom

11. Division of Infectious Diseases, School of Medicine, University of Virginia,

Charlottesville, United States of America

12. European Bioinformatics Institute, Hinxton, UK

13. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South

Africa

Corresponding author: Bernadette Young (Bernadette.young@ndm.ox.ac.uk)

Abstract

Viral sequencing has been critical in the COVID-19 pandemic response, but sequencing and bioinformatics capacity remain inconsistent. To examine the utility of a cloud-based sequencing analysis platform for SARS-CoV-2 sequencing, we conducted a cross-sectional study incorporating seven countries in July 2022. Sites submitted sequential SARS-CoV-2 sequences over two weeks to the Global Pathogen Analysis Service (GPAS). The GPAS bioinformatics cloud platform performs sequence assembly plus lineage and related sample identification. Users can share information with collaborators while retaining data ownership. Seven sites contributed sequencing reads from 5,346 clinical samples, of which 4,799/5,346 (89.8%) had a lineage identified. Omicron lineages dominated, with the vast majority being BA.5, BA.4 and BA.2, commensurate with contemporary genomic epidemiological observations. Phylogenetic analysis demonstrated low within-lineage diversity, and highly similar sequences present in globally disparate sites. A cloud-based analysis platform like GPAS addresses bioinformatics bottlenecks and facilitates collaboration in pathogen surveillance, enhancing epidemic and pandemic preparedness.

Introduction

Viral genomic sequencing has been pivotal in understanding and responding to SARS-CoV-2 viral evolution during the COVID-19 pandemic. Global sharing of data and comparison of samples has facilitated public health surveillance by tracking the emergence of variants globally,[1] demonstrating the impact of travel restrictions on viral dynamics across continents,[2] and of travel and quarantine on spread within countries,[3,4] as well as demonstrating transmission routes within hospitals.[5] As successive waves driven by new viral variants emerged, it became clear that rapidly detecting new lineages is critical both for understanding and predicting disease epidemiology as well as for guiding both public health measures and treatment of infection, including the use of neutralising antibodies.[6,7] However there remains marked global variability in sequencing costs and capacity.[8] Much SARS-CoV-2 sequencing has been undertaken at centralised reference laboratories, but the speed and power of this tool is greatly enhanced when researchers and clinicians at any location can contribute to the global view of viral evolution and surveillance.[9]

Several important challenges remain in expanding pathogen genomic surveillance, including access to sequencing technology, the availability of bioinformatic resources and the global interpretability of results generated using different bioinformatics approaches.[10,11,12] One solution to the relative shortage of bioinformatic expertise in many settings is web-accessible analysis infrastructure.[13] The Global Pathogen Analysis Service (GPAS) is a cloud-based globally web-accessible platform that provides secure and rapid access to comprehensive SARS-CoV-2 sequencing genome assembly and analysis software. GPAS supports multiple sequencing platforms and tiling PCR primer schemes, and has been validated against widely used methods. Users can opt to share their data on this platform, allowing those who opt in to view their own results in a wider context, facilitating comparisons for rapid and comprehensive assessments of viral data. The platform is designed for use by clinical and public health laboratory scientists and has been established and used for over a year in a tertiary hospital based clinical microbiology laboratory to ISO15189:2012 standards. Scaling

up this simple-to-use assembly, variant calling and analysis tool for SARS-CoV-2 empowers

laboratories to control the analysis of their sequence data. It provides proof of principle that

standard microbiology laboratories without bioinformatics expertise from across the world

can generate outputs for local surveillance and automated submission to public databases.

Such a service is an exemplar of how cloud-based services, accessible in all settings with

internet access, offer great promise for overcoming an important barrier to effective genomic

surveillance.

The primary aim of this project was to demonstrate that a globally broad snapshot of SARS-

CoV-2 viral diversity can be simultaneously gathered, processed and shared through a cloud-

based software, enabling aggregation for combined descriptive analysis.

Methods

Sample frame and sequencing: Sequencing centres participated in a two-week pilot in July to

August 2022. Centres were from seven countries: Senegal; Chile; South Africa; New South

Wales (NSW), Australia; Vietnam; United Kingdom; Virginia, United States (USA). Centres

were either accredited clinical microbiology or public health laboratories. All clinical

samples in which SARS-CoV-2 was detected were eligible for inclusion and underwent in-

house genomic sequencing at participating sites during the pilot were eligible for inclusion,

with no more than one submission from an individual patient.

Sequencing was performed using either Illumina or Oxford Nanopore Technology (ONT)

platforms. Multiple primer schemes were supported (ARTIC V3, V4 or 4.1, and Midnight).

Sequencing platform and primer schemes were chosen by participating sites, who followed

their established sequencing protocols.

Bioinformatic methods: Unselected raw sequences were submitted to GPAS in FASTQ

format with sequencing information (instrument platform, primer scheme) and limited

associated metadata (sample name, whether sequence data was a control or study sample,

collection date, country of origin). At upload, a Universally Unique IDentifier (UUID) was

randomly generated and assigned to each sample. The mapping between the centre's sample

identifier and the GPAS UUID was held only by the submitting organisation, ensuring that no

potentially personally identifiable information was transmitted to the GPAS platform. When

results were returned to the submitter after analysis, they could hence be re-linked to the

subject's record. At upload, only reads mapping to SARS-CoV-2 were kept,[14] guaranteeing

that no human reads were retained and pushed to the cloud. Tight access control to data

applied within GPAS. With the permission of all collaborators, data access controls were

configured such that all submitters could access each other's sequences, metadata and

analytical output data for the duration of the investigation.

Sequence data analysis was performed by the GPAS SARS-CoV-2 bioinformatics pipeline.

Genome assembly was performed by an amplicon-aware *de novo* genome assembly tool

Viridian v0.3.7.[15] Viridian applies quality control (QC) at both a read and amplicon level,

to produce a consensus assembly. Each genomic position is called A,C,G or T only where 10

or more reads passing amplicon-aware QC provide at least 70% support, otherwise it is called

ambiguously as N. After assembly, clade assignment and amino acid mutation calls were

made using Nextclade,[16] and Pango lineages assigned with Pangolin.[17] Samples were

further labelled according to the United Kingdom Health Security Agency (UKHSA)

nomenclature to define and track variants of concern using aln2type.[18] The GPAS QC suite

provided read-level QC output for each sample, reporting the number of mapped reads per

sample, median read depth, reference coverage at read depths of 10 and 20, and the number

of amplicons failing quality control. Consensus genome assemblies were aligned by Viridian

to the Wuhan-Hu-1 reference genome (MN908947.3).[19] Aligned sequences were compared

using findNeighbour4, which identifies sequences without conflicting variant calls (0 single

nucleotide variants (SNVs)), as well as those differing by one, two and three SNVs.[20,21]

Submitting sites verified the run quality reports of each sequencing batch, including review

of positive and negative controls, and outputs were passed or failed accordingly. All passed

samples were tagged for aggregate analysis, and released to the GPAS shared data pool,

which identifies other samples within three SNVs in the shared data pool. The GPAS

platform recorded the total number of sequencing runs and total number of samples. Analysis

duration was also monitored, along with descriptive reports of any unexpected issues with the

platform.

Phylogenetic analysis: In Oxford, genome assemblies in the shared data pool were

downloaded from the GPAS portal. A maximum likelihood phylogeny of aligned sequences

was constructed for the three largest Pango lineages in the sample set (BA.5, BA.4 and BA.2)

in using RAxML [22] (assuming a general time reversible (GTR) nucleotide substitution

model).

Results

All sites tagged their sequencing data and results granting access for aggregated analysis.

5,437 sequences were shared (Table 1, Table S1). As different sequencing centres worked

with samples collected at different times, the date of collection of submitted sequences varied

by centre, ranging from April to July 2022. Of submitted samples 91 (1.7%) were controls

and 5,346 (98.3%) were clinical samples Among these, 4,797/5,346 (89.7%) were assembled

with at least 70% coverage (at a depth of 10 reads), and 4,799/5,346 (89.8%) were assembled

with sufficient coverage to be assigned a lineage (Table 2). 4,775/4,799 (99.5%) were

Omicron variants, with BA.5, BA.4 and BA.2 being the most common. A small number of

Delta variant sequences were identified (23/4,799 0.5%), all of which were collected prior to

July 2022.

Table 1: Samples submitted by study centre, with date of collection and genome coverage

(with minimum depth of 10 reads)

Centre	Submitted	Controls	<50% coverage	50-70% coverage	>70% coverage	Earliest sequence	Latest sequence
Senegal	197	0	14	10	173	13th July 2022	20th July 2022
Chile	1205	20	4	7	1174	16th June 2022	21st July 2202
South Africa	202	0	9	4	189	17th May 2022	24th June 2022
NSW, Australia	1194	31	34	23	1106	21st June 2022	18th July 2022
Vietnam	316	3	20	5	288	1st April 2022	14th July 2022
United Kingdom	1823	37	319	100	1367	12th July 2022	26th July 2022
Virginia, USA	500	0	0	0	500	7th June 2022	29th June 2022
Total	5437	91	400	149	4797	1st April 2022	26th July 2022

177   Table 2: SARS-CoV-2 lineage by study centre (where a lineage was assigned by Pangolin)

	Omicron							Delta	Alpha	Other	
Centre	BA.5	BA.4	BA.2	BE.1	BF.1	BA.1	BG.2	Delta	B.1.1.7	B.28	Total
Senegal	69	47	34	5	18	0	0	0	0	0	173
Chile	397	607	145	20	4	0	0	0	0	0	1,173
South Africa	89	86	3	6	0	5	0	0	0	0	189
NSW, Australia	736	130	184	54	3	0	0	0	0	0	1,107
Vietnam	8	0	256	0	0	4	0	22	0	0	290
United Kingdom	974	169	57	140	23	2	0	0	1	1	1,367
Virginia, USA	95	94	296	11	1	1	1	1	0	0	500
Total	2,368	1,133	975	236	49	12	2	23	1	1	4,799

Comparing only clinical samples collected between 1st June 2022 and 31st July 2022, the

proportion of samples assigned to the different Omicron sub-lineages varied substantially by

study site (Figure 1). Each of BA.2, BA.4 or BA.5 dominated (constituted >50% of samples

from) at least one site, while Senegal had no single dominant lineage. For each of the three

most common lineages, a maximum likelihood phylogeny was constructed to compare

diversity within and between sites (Figure 2).

Phylogenetic analysis revealed global mixing of Omicron lineages. There were no examples

of sub-lineages being completely geographically restricted within this study. One sub-lineage

in BA.4 was predominantly found in Chile (Figure 2), however examples of this sub-lineage

were also identified in the United Kingdom. Similarly, a sub-lineage of BA.2 was mainly

found in Vietnam (Figure 2) but again an example of this genotype was found in the United

Kingdom.

Highly genetically similar samples were identified within lineages from globally distinct

sites, with branch lengths corresponding to $\leq 0.01\%$ of the genome (approximately three

nucleotides) separating many samples. This limited diversity was further explored by

examining the relative likelihood of samples being from the same site with increasing

genomic variation. By this measure, the greatest dispersal was seen within the BA.4 lineage

(Figure 3). In total 357/1,133 of BA.4 samples were genotypically identical to another

sequenced sample. Among these, 244/357 (68.4%) were only identical to other samples from

the same study centre. Allowing for just one single nucleotide variant (SNV) reduced the

proportion of closely related samples to the same study centre (and country) to 302/634

(47.6%). The proportions reduced to 279/819 (34.1%) and to 201/923 (21.8%) when allowing

for two and three SNVs respectively. Only 210/1,133 (18.5%) did not have a related sample

allowing up to three SNVs. The other major lineages BA.2 and BA.5 likewise showed

evidence of genotypically identical sequences identified at different study sites, with

increasing evidence of dispersal as SNV threshold increased (Figure 3).

Cloud processing performance was measured by time elapsed from upload until completion

of processing. The median sample processing time was 30.6 minutes (IQR 13.1-69.9

minutes). The distribution of processing times was much wider than expected, and processing

delays occurred for several batches from Australia, United Kingdom and United States

(Figure S1). Some of these coincided with data centre outages during an extreme heat event

in the United Kingdom, while other delays occurred due to errors in a software update for the

upload portal, which were resolved by improvements implemented in the user side command

line interface software. Other data upload issues were identified and addressed in real time,

including metadata file formatting errors, availability of upload clients for all required

operating systems, and user interface display errors preventing batch release.

Discussion

This pilot study reveals the potential for cloud-based synchronous global data processing and

analysis for public health. The GPAS platform provides an example of unified assembly,

variant calling and analysis of data from participating centres, which can facilitate both local

and globally aggregated analysis. In this cross-sectional observational study, the aggregate

analysis conforms to contemporary observations of SARS-CoV-2 genetic

epidemiology[23,24,25,26,27], though these observations remain limited by global disparities

in sequencing volume.

The opportunistic sampling frame used means this study is likely to be geographically

incomplete, but even with this limitation we observed cosmopolitan global mixing of

Omicron lineages between study sites. Even a BA.4 sub-lineage which demonstrated

extensive replacement in one geographical location (Chile) was not completely restricted to

that site and could be identified in a geographically distant site (United Kingdom). During the

period of the study, the United Kingdom site performed genomic sequencing on all clinical

isolates which had tested positive for SARS-CoV-2 on PCR, and despite being dominated by

BA.5, was also able to identify examples of a BA.2 sub-lineage that was otherwise restricted

to Vietnam. Such mixing is likely the result of movement for travel and migration, as SARS-

CoV-2 related travel restrictions had been relaxed in the countries with participating sites.

Given evidence of global mixing and limited diversity between sites, viral genome

sequencing is limited in its ability to inform studies of local viral transmission in this

Omicron dominated era, where both rapid global mixing and transmission drives spread.[26]

Allowing for up to three different single nucleotide variants, the majority of isolates from the

dominant lineages BA.2, BA.4 and BA.5 had at least one closely related sample within each

countries' contemporaneously sequenced samples. Depending on lineage, between 10.0%

and 31.5% of genotypically identical sequences in this study were identified in different

countries and continents. The use of a shared bioinformatics analysis pipeline, as described

here, highlights how lineages can be simultaneously and confidently mapped across distant

sites. This captures the evidence of well described rapid global dispersal of Omicron lineages

with successive selective sweeps of these new Omicron variants over short time scales.[27]

These observations highlight the potential for deriving insights from viral sequencing at a few

globally distributed sites. While this study pertains to a specific point in the pandemic, it

raises the question of how to better design genomic surveillance balancing the public health

need and available resources. It is recognised that a preponderance of sequence data came

from high-income countries, who sequenced a proportion of cases ten-fold higher than that

achieved in low- and middle-income counties during the first two years of the pandemic.[9]

Nor was the data collected evenly over the course of pandemic. In retrospect this was not

optimal. Better designed representative sampling would be immensely empowering and is

likely possible through well-designed and suitably powered sampling frames. Ideally, this

would be addressed through pandemic preparedness planning, enabling sequencing to be

focussed at selected sentinel sites globally cognisant of national jurisdictions and the benefit

of longitudinal data, as exemplified by a cohort design in the UK.[25]

Pathogen sequencing played a highly valuable role in the COVID-19 pandemic and remains a

critical global and national capability. This is highlighted by studies of viral transmission that

have yielded important insights into the modes of pathogen spread.[1-5] In addition,

identification of emerging variants-of-concern guided public health and policy responses,[28]

as well as informing assessments about the impact of emerging variants on the impact of

therapeutics (such as monoclonal antibodies) and vaccines.[7,29] The present cross-sectional

study has the limitation of lacking longitudinal data on how these findings changed over time.

Nevertheless, this study demonstrates how simply structured sampling across the world is

well placed to rapidly identify replacement by new lineages. The integration of genomic data

with subject disease manifestation and severity data would enable the ready investigation of

associations between genomic variation and severity of disease, as suggested by others [30]

and predictive modelling for anticipating the course of future epidemics as described so

effectively early in the SARS-CoV-2 pandemic [31].

The world is now better prepared to urgently initiate genomic pathogen surveillance. The

available sequencing platform capacity is much improved, and the achievements of global

data aggregation (illustrated by INSDC and GISAID databases) has alleviated a major

obstacle to effective genomic surveillance. A remaining obstacle is local turnkey

bioinformatics to perform sequence assembly, variant calling and analysis. These are needed

to deliver standardised and quality assured outputs – specifically the SARS-CoV-2 viral

sequence FASTA file – for phylogenetic analysis either for global analysis by an

international entity such as GISAID, or for local and national analyses. GPAS has developed

an exemplar cloud-based, web-enabled service design that is optimised for operation by a

laboratory scientist and removes dependence on in-laboratory bioinformatics expertise. Thus,

this work reveals the benefit of establishing software for simply and automatically ingesting

sequence data from a sequencer in a local lab and yielding data ready for local or

international analysis. A software infrastructure such as the GPAS platform fills a gap in

delivering global genomic surveillance. Flexible privacy protections allows users to control

sharing of genomic data. GPAS is freely available to low- and middle-income countries,

reducing some of the barriers to analysis services in low resource settings. Remaining

challenges include high speed computer network access and local epidemiological tools, and

expertise for detailed epidemiological analysis.

Conclusions

The COVID-19 pandemic has demonstrated the multiple ways in which viral sequencing can

inform pandemic responses, but resources and capabilities are not equitably distributed. A

service like GPAS democratises SARS-CoV-2 genomics, enabling researchers and

laboratories, regardless of their location or level of bioinformatics expertise, to participate

actively in global surveillance efforts. By providing accessible and user-friendly tools for

sequence assembly, lineage assignment, and data sharing, it fosters collaboration, harmonises

data, and ultimately enhances pandemic preparedness.

Funding statement

GPAS is free at the point of use for users in low- and middle-income countries. GPAS was

developed specifically to minimise the need for bioinformatics staff (a scarce and expensive

resource), to help bring genomic insights within reach for laboratories with limited resources.

GPAS operates as a non-profit organisation. All GPAS SARS-CoV-2 services were offered

free of charge to all sites for the purposes of this study. Staff costs for the 5C analysis team

were met by the University of Oxford.

The cloud infrastructure used in this study was donated by Oracle Corporation.

Sequencing activities for NICD are supported by a conditional grant from the South African

National Department of Health as part of the emergency COVID-19 response; a cooperative

agreement between the National Institute for Communicable Diseases of the National Health

Laboratory Service and the United States Centers for Disease Control and Prevention

(NU51IP000930); the South African Medical Research Council (SAMRC) with funds

received from the South African Department of Science and Innovation; the African Society

of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention

through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978;

Africa PGI, the UK Foreign, Commonwealth and Development Office and Wellcome (Grant

no 221003/Z/20/Z); and the Department of Health and Social Care's Fleming Fund using UK

aid.. NICD sequencing was also supported by The Coronavirus Aid, Relief, and Economic

Security Act (CARES ACT) through the Centers for Disease Control and Prevention (CDC)

and the COVID International Task Force (ITF) funds through the CDC under the terms of a

subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021.

Genomic surveillance conducted in Vietnam was supported by the Wellcome Trust

(222574/Z/21/Z). L.V.T. is supported by the Wellcome Trust of Great Britain

(204904/Z/16/Z and 226120/Z/22/Z).

Ethical statement

SARS-CoV-2 sequencing was performed for public health surveillance and ethical approval

for secondary analysis was not required. This determination was reviewed by the University

of Oxford Joint Research Office. No patient identifying information was shared as part of this

study. Sample identifiers remain with the submitter, and are never kept on GPAS or shared

with other users. GPAS generates identifiers for each sequence and writes a file linking

anonymised ID to the submitted identifiers. Only the user submitting sequence data has

access to these records. The GPAS upload client selects only SARS-CoV-2 sequence reads

and discards non SARS-CoV-2 reads (including all human sequences).

Data availability

Submitted sequencing reads (free from human reads) for all included samples are available

from European Nucleotide Archive study accession PRJEB70597.

Conflicts of interest

AvG and NW have received grant funding from Sanofi and The Bill and Melinda Gates

Foundation.

Authors

All authors have seen and approved the manuscript

Acknowledgments

• El Instituto de Salud Pública de Chile, Chile

• Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for

Communicable Diseases (NICD), a division of the National Health Laboratory

Service, South Africa

• The Institut Pasteur de Dakar, Senegal

• Oxford University Hospitals NHS Trust, Oxford, United Kingdom

• University of Virginia, Charlottesville, United States of America

• Oxford University Clinical Research Unit, Vietnam

• Hospital for Tropical Diseases SARS-CoV-2 testing team, HTD Vietnam: Le

Manh Hung, Nguyen Le Nhu Tung, Nguyen Thanh Phong, Vo Minh Quang,

Pham Thi Ngoc Thoa, Nguyen Thanh Truong, Tran Nguyen Phuong Thao,

Dao Phuong Linh, Ngo Tan Tai, Ho The Bao, Vo Trong Vuong, Huynh Thi

Kim Nhung

• Oracle Global Health Business Unit

References

1. Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of

SARS-CoV-2. Nature. 2021 Dec;600(7889):408-418. doi: 10.1038/s41586-021-

04188-6.

2. Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, et al. A year of

genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa.

Science. 2021 Oct 22;374(6566):423-431. doi: 10.1126/science.abj4336.

3. McCrone JT, Hill V, Bajaj S, Pena RE, Lambert BC, Inward R, et al. Context-specific

emergence and growth of the SARS-CoV-2 Delta variant. Nature. 2022

Oct;610(7930):154-160. doi: 10.1038/s41586-022-05200-3.

4. Raghwani J, du Plessis L, McCrone JT, Hill SC, Parag KV, Thézé J, et al. Genomic

Epidemiology of Early SARS-CoV-2 Transmission Dynamics, Gujarat, India. Emerg

Infect Dis. 2022 Apr;28(4):751-758. doi: 10.3201/eid2804.212053.

388 5. Snell LB, Fisher CL, Taj U, Stirrup O, Merrick B, Alcolea-Medina A, et al.

389   Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2

390   infection early in the pandemic and the role of unidentified cases in transmission. Clin

391   Microbiol Infect. 2022 Jan;28(1):93-100. doi: 10.1016/j.cmi.2021.07.040

392 6. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The

393   biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev

394   Genet. 2021 Dec;22(12):757-773. doi: 10.1038/s41576-021-00408-x.

395 7. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et

396   al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and

397   BA.1 serum. Cell. 2022 Jul 7;185(14):2422-2433.e13. doi:

398   10.1016/j.cell.2022.06.005. Epub 2022 Jun 9. PMID: 35772405; PMCID:

399   PMC9181312.

400 8. Merhi G, Koweyes J, Salloum T, Khoury CA, Haidar S, Tokajian S. SARS-CoV-2

401   genomic epidemiology: data and sequencing infrastructure. Future Microbiol. 2022

402   Sep;17:1001-1007. doi: 10.2217/fmb-2021-0207.

403 9. Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, et al.

404   Global disparities in SARS-CoV-2 genomic surveillance. Nat Commun. 2022 Nov

405   16;13(1):7003. doi: 10.1038/s41467-022-33713-y

406 10. Global genomic surveillance strategy for pathogens with pandemic and epidemic

407   potential, 2022–2032. Geneva: World Health Organization; 2022. Licence: CC BY-

408   NC-SA 3.0 IGO

409 11. Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-

410   informed pathogen surveillance in Africa: opportunities and challenges. Lancet Infect

411   Dis. 2021 Sep;21(9):e281-e289. doi: 10.1016/S1473-3099(20)30939-7

412 12. Chen Z, Azman AS, Chen X, Zou J, Tian Y, Sun R, et al. Global landscape of SARS-

413   CoV-2 genomic surveillance and data sharing. Nat Genet. 2022 Apr;54(4):499-507.

414   doi: 10.1038/s41588-022-01033-y.

13. Ohlsen EC, Hawksworth AW, Wong K, Guagliardo SAJ, Fuller JA, Sloan ML, et al.
Determining Gaps in Publicly Shared SARS-CoV-2 Genomic Surveillance Data by
Analysis of Global Submissions. Emerg Infect Dis. 2022 Dec;28(13):S85-S92. doi:
10.3201/eid2813.220780.

14. Hunt M, Swann J, Constantinides B, Fowler PW, Iqbal Z. ReadItAndKeep: rapid
decontamination of SARS-CoV-2 sequencing reads. Bioinformatics. 2022 Jun
13;38(12):3291-3293. doi: 10.1093/bioinformatics/btac311.

15. https://github.com/iqbal-lab-org/viridian_workflow/wiki

16. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,
mutation calling and quality control for viral genomes. Journal of Open Source
Software, 2021 6(67): 3773, https://doi.org/10.21105/joss.03773

17. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al.
Assignment of epidemiological lineages in an emerging pandemic using the pangolin
tool. Virus Evol. 2021 Jul 30;7(2):veab064. doi: 10.1093/ve/veab064.

18. https://github.com/connor-lab/aln2type

19. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
associated with human respiratory disease in China. Nature. 2020
Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3

20. Mazariegos-Canellas O, Do T, Peto T, Eyre DW, Underwood A, Crook D, et al
BugMat and FindNeighbour: command line and server applications for investigating
bacterial relatedness. BMC Bioinformatics. 2017 Nov 13;18(1):477. doi:
10.1186/s12859-017-1907-2.

21. https://github.com/davidhwyllie/findNeighbour4

22. Stamatakis A. RAxML version 8: A tool for phylogenetic analysis and post-analysis
of large phylogenies Bioinformatics. 2014; 30(9),1312-3 doi:
10.1093/bioinformatics/btu033.

23. World Health Organisation Coronavirus (COVID-19) Dashboard,
https://covid19.who.int [Accessed 19th April 2023]

24. Tosta S, Moreno K, Schuab G, Fonseca V, Segovia FMC, Kashima S, et al. Global
SARS-CoV-2 genomic surveillance: What we have learned (so far). Infect Genet
Evol. 2023 Mar;108:105405. doi: 10.1016/j.meegid.2023.105405.

25. Foulkes S, Monk EJM, Sparkes D, Hettiarachchi N, Milligan ID, Munro K, et al.
Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom,
November 2021-September 2022. Emerg Infect Dis. 2023 Jan;29(1):184-188. doi:
10.3201/eid2901.221293.

26. Xu Y, Liu T, Li Y, Wei X, Wang Z, Fang M, et al. Transmission of SARS-CoV-2
Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. Microbiol
Spectr. 2023 Mar 14;11(2):e0463222. doi: 10.1128/spectrum.04632-22.

27. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The
evolution of SARS-CoV-2. Nat Rev Microbiol. 2023 Apr 5. doi: 10.1038/s41579-
023-00878-2.

28. WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution, Updated working
definitions and primary actions for SARS-Cov-2 variants, World Health Organisation,
March 2023. https://www.who.int/publications/m/item/updated-working-definitions-
and-primary-actions-for--sars-cov-2-variants [Accessed 19th April, 2023]

29. Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, et al.
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral
responses and resistance to clinical immunotherapeutics relative to viral variants of
concern. EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270.

30. Oude Munnink BB, Worp N, Nieuwenhuijse DF, Sikkema RS, Haagmans B,
Fouchier RAM, et al The next phase of SARS-CoV-2 surveillance: real-time
molecular epidemiology. Nat Med. 2021 Sep;27(9):1518-1524. doi: 10.1038/s41591-
021-01472-w.

31. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021
May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x.

Figures

Figure 1: Omicron sub-lineages by study site. Proportion of samples assigned to Omicron

sub-lineage within each study site, where collection date was in June or July 2022.

Figure 2: Maximum likelihood phylogeny of isolates from each major lineage (BA.2, BA.4,

BA.5) found in seven centres. Final branches are coloured according the centre in which they

were sequenced.

Figure 3: Percentage of related samples which are restricted to the same study site, allowing

for 0, 1, 2 and 3 SNVS as the threshold for relatedness, for 3 major lineages (BA.2, BA.4 and

BA.5).

Figure S1: Distribution of processing time (in minutes) for each sample in GPAS pipeline

according to submitting site (a) all samples and (b) samples processed in under 1000 minutes

492